Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Exagen (XGN) Operating Expenses (2018 - 2026)

Exagen filings provide 9 years of Operating Expenses readings, the most recent being $13.6 million for Q1 2026.

  • On a quarterly basis, Operating Expenses rose 9.06% to $13.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $54.0 million, a 13.36% increase, with the full-year FY2025 number at $52.9 million, up 13.09% from a year prior.
  • Operating Expenses hit $13.6 million in Q1 2026 for Exagen, down from $14.2 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $27.3 million in Q4 2022 to a low of -$4.2 million in Q4 2023.
  • Median Operating Expenses over the past 5 years was $13.6 million (2026), compared with a mean of $15.1 million.
  • Biggest five-year swings in Operating Expenses: crashed 115.3% in 2023 and later skyrocketed 383.73% in 2024.
  • Exagen's Operating Expenses stood at $27.3 million in 2022, then tumbled by 115.3% to -$4.2 million in 2023, then skyrocketed by 383.73% to $11.9 million in 2024, then increased by 19.57% to $14.2 million in 2025, then dropped by 3.96% to $13.6 million in 2026.
  • The last three reported values for Operating Expenses were $13.6 million (Q1 2026), $14.2 million (Q4 2025), and $13.2 million (Q3 2025) per Business Quant data.